



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,806	12/01/2003	Randy D. Blakely	VBLT:008USD1	3686

7590 08/09/2006

Steven L. Highlander, Esq.
FULBRIGHT & JAWORSKI L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701

EXAMINER

BUNNER, BRIDGET E

ART UNIT PAPER NUMBER

1647

DATE MAILED: 08/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/724,806	Applicant(s) BLAKELY ET AL.	
	Examiner Bridget E. Bunner	Art Unit 1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 June 2004.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 29-36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 29-36 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 09 June 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>3/5/04</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Appendices A, B, C, D</u> |

DETAILED ACTION

Status of Application, Amendments and/or Claims

The amendment of 01 December 2003 has been entered in full. Claims 1-28 and 37-105 are cancelled.

Claims 29-36 are under consideration in the instant application.

Information Disclosure Statement

The information disclosure statement filed 05 March 2004 fails to comply with 37 CFR 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language (document DE 10009055). It has been placed in the application file, but the information referred to therein has not been considered.

Sequence Compliance

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). **Specifically, the sequences disclosed in Figure 2 and Figure 4 are not accompanied by the required reference to the relevant sequence identifiers.** This application fails to comply with the requirements of 37 CFR 1.821 through 1.825. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825).

Claim Objections

2. Claim 29 is objected to because of the following informalities:

Art Unit: 1647

2a. In claim 29, line 1 is missing the term “acid” after “amino”. Appropriate correction is required.

Specification

3. The disclosure is objected to because of the following informalities:

3a. Patent applications are referenced throughout the disclosure (for example, pg 136, line 22). The status of the applications must be updated.

3b. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (See for example, pg 20, line 20; pg 25, line 17; pg 46, line 24). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

3c. The Brief Description of Drawings for Figure 11 at pg 10-11 of the specification does not refer to Figures 11C or 11D.

3d. The Brief Description of Drawings for Figure 14 at pg 11 of the specification does not refer to Figures 14A and 14B.

3e. The reference cited at pg 3, line 10 (Apparsundaram 2001) needs to be updated as it is still listed as “in press”.

3f. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: “POLYNUCLEOTIDE ENCODING A MURINE CHOLINE TRANSPORTER”.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 29-36 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 4 and for an isolated polynucleotide comprising the nucleic acid sequence as set forth in SEQ ID NO: 3, does not reasonably provide enablement for an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence essentially as set forth in SEQ ID NO: 4 or for an isolated polynucleotide comprising the nucleic acid sequence essentially as set forth in SEQ ID NO: 3. The specification is also not enabling for a purified and isolated polynucleotide comprising a sequence identical or complementary to between 10 and 100 contiguous nucleotides of SEQ ID NO: 3. The specification is also not enabling for a recombinant vector or recombinant host cell comprising a DNA segment encoding any isolated murine choline transporter. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

It is noted that the phrases “comprising/having ...essentially as set forth in SEQ ID NO:”, “an isolated choline transporter” (for example, claim 34), and “(c)DNA segment” as recited in the claims, are broadly interpreted by the Examiner as reading upon: (i) nucleic acid variants of SEQ ID NO: 3 with any number of deletions, substitutions, or additions and (ii) protein variants of SEQ ID NO: 4 with any number of deletions, substitutions, or additions.

Specifically, the claims are directed to an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence essentially as set forth in SEQ ID NO: 4 and an isolated polynucleotide comprising the nucleic acid sequence essentially as set forth in SEQ ID NO: 3. The claims also recite a purified and isolated polynucleotide comprising a sequence identical or complementary to between 10 and 100 contiguous nucleotides of SEQ ID NO: 3. The claims recite that the polynucleotide is comprising in a vector. The claims also recite a recombinant vector comprising a DNA segment encoding a mouse choline transporter polypeptide under the control of a promoter.

The specification of the instant application teaches that nucleic acid variants may be any length and that "a DNA segment encoding CHT refers to a DNA segment that contains wild-type, polymorphic or mutant CHT coding sequences yet is isolated away from, or purified free from, total mammalian genomic DNA. Included within the term "DNA segment," are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like" (pg 23, lines 7-12; pg 30; pg 42). The specification teaches only teaches a murine CHT polynucleotide and polypeptide of SEQ ID NO: 3 and SEQ ID NO: 4, respectively. The specification does not teach any variants, fragments, or derivatives of the nucleic acid sequence of SEQ ID NO: 3. The specification does not teach any variants, fragments, or derivatives of a polynucleotide that encodes the polypeptide of SEQ ID NO: 4. The specification also does not teach all possible DNA segments that encode an isolated murine choline transporter. Further, the specification does not teach functional or structural characteristics of the polynucleotide variants, fragments, or derivatives in the context of a cell or organism.

The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the DNA and amino acid sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These or other regions may also be critical determinants of antigenicity. These regions can tolerate only relatively conservative substitutions or no substitutions (see Wells, 1990, *Biochemistry* 29:8509-8517; Ngo et al., 1994, *The Protein Folding Problem and Tertiary Structure Prediction*, pp. 492-495). For example, Okuda et al. (*J Biol Chem* 277(47): 45315-45322, 2002) teach that a single amino acid change from an isoleucine to a valine at amino acid position 89 in the human choline transporter causes a 40-50% decrease in choline uptake as compared with wild-type (pg 45317, col 2, ¶ 2; pg 45319, col 1-2; Figure 3, Table II, Figure 6B, C). Okuda et al. also demonstrate that introduction of an isoleucine in place of valine at corresponding amino acid position 90 in the *C. elegans* ortholog (CHO-1) also causes a 40% decrease in choline uptake with unaltered affinity for choline (pg 45319, col 2 through pg 45320, col 1; Figure 6D, E).

However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the DNA and protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made

Art Unit: 1647

in these positions. Although the specification outlines art-recognized procedures for producing and screening for active muteins, this is not adequate guidance as to the nature of active derivatives that may be constructed, but is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. Even if an active or binding site were identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity. The art recognizes that function cannot be predicted from structure alone (Bork, 2000, *Genome Research* 10:398-400; Skolnick et al., 2000, *Trends in Biotech.* 18(1):34-39, especially p. 36 at Box 2; Doerks et al., 1998, *Trends in Genetics* 14:248-250; Smith et al., 1997, *Nature Biotechnology* 15:1222-1223; Brenner, 1999, *Trends in Genetics* 15:132-133; Bork et al., 1996, *Trends in Genetics* 12:425-427).

Additionally, the Examiner has interpreted claims 89-91 as reading on isolated host cells, as well as host cells in the context of a multicellular, transgenic organism and host cells intended for gene therapy. The specification of the instant application teaches that CHT gene product can be expressed in transgenic animals (for example pg 7, lines 28-29; pg 8, lines 1-8). However, there are no methods or working examples disclosed in the instant application whereby a multicellular animal with the incorporated mCHT gene of SEQ ID NO: 3 is demonstrated to express the mCHT polypeptide. The unpredictability of the art is *very high* with regards to making transgenic animals. For example, Wang et al. (*Nuc. Acids Res.* 27: 4609-4618, 1999; pg 4617) surveyed gene expression in transgenic animals and found in each experimental animal

Art Unit: 1647

with a single "knock-in" gene, multiple changes in genes and protein products, often many of which were unrelated to the original gene. Likewise, Kaufman et al (Blood 94: 3178-3184, 1999) found transgene expression levels in their transfected animals varied from "full" (9 %) to "intermediate" to "none" due to factors such as "vector poisoning" and spontaneous structural rearrangements (pg 3180, col 1, 2nd full paragraph; pg 3182-3183). Therefore, , it would have required undue experimentation for the skilled artisan to have made any and all transgenic non-human animals according to the instant invention.

The specification also discloses that nucleic acids encoding the mCHT polypeptide can be used for gene therapy (pg 3, line 22). However, the specification does not teach any methods or working examples that indicate a mCHT nucleic acid is introduced and expressed in a cell for therapeutic purposes. The disclosure in the specification is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. For example, the specification does not teach what type of vector would introduce the mCHT nucleic acid into the cell or in what quantity and duration. Relevant literature teaches that since 1990, about 3500 patients have been treated via gene therapy and although some evidence of gene transfer has been seen, it has generally been inadequate for a meaningful clinical response (Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001; abstract). Additionally, the major challenge to gene therapy is to deliver DNA to the target tissues and to transport it to the cell nucleus to enable the required protein to be expressed (Phillips, A.; pg 1170, ¶ 1). Phillips also states that the problem with gene therapy is two-fold: 1) a system must designed to deliver DNA to a specific target and to prevent degradation within the body, and 2) an expression system must be built into the DNA construct to allow the target cell to express the protein at therapeutic levels for the desired length

Art Unit: 1647

of time (pg 1170, ¶ 1). Therefore, undue experimentation would be required of the skilled artisan to introduce and express a mCHT nucleic acid into the cell of an organism. Additionally, gene therapy is unpredictable and complex wherein one skilled in the art may not necessarily be able to introduce and express a mCHT nucleic acid in the cell of an organism or be able to produce a mCHT protein in that cell. (Please note that this issue could be overcome by amending the claims to recite, for example, "An isolated host cell...").

Due to the large quantity of experimentation necessary to generate the infinite number of derivatives recited in the claims and possibly screen the same for activity, and to generate a transgenic animal expressing the mCHT protein and to introduce and express a mCHT nucleic acid in a cell of an organism for therapy; the lack of direction/guidance presented in the specification regarding which structural features are required in order to provide activity and how to introduce a mCHT nucleic acid in the cell of an organism to be able produce that mCHT; the absence of working examples directed to same; the complex nature of the invention; the state of the prior art which establishes the unpredictability of the effects of mutation on protein structure and function and the unpredictability of making transgenic animals and of transferring genes into an organism's cells; and the breadth of the claims which fail to recite any structural or functional limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

5. Claims 29-36 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant

Art Unit: 1647

art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Specifically, the claims are directed to an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence essentially as set forth in SEQ ID NO: 4 and an isolated polynucleotide comprising the nucleic acid sequence essentially as set forth in SEQ ID NO: 3. The claims also recite a purified and isolated polynucleotide comprising a sequence identical or complementary to between 10 and 100 contiguous nucleotides of SEQ ID NO: 3. The claims recite that the polynucleotide is comprising in a vector. The claims also recite a recombinant vector comprising a DNA segment encoding a mouse choline transporter polypeptide under the control of a promoter.

It is noted that the phrases “comprising/having ... essentially as set forth in SEQ ID NO:”, “an isolated choline transporter” (for example, claim 34), and “(c)DNA segment” as recited in the claims, are broadly interpreted by the Examiner as reading upon: (i) nucleic acid variants of SEQ ID NO: 3 with any number of deletions, substitutions, or additions and (ii) protein variants of SEQ ID NO: 4 with any number of deletions, substitutions, or additions.

The specification of the instant application teaches that nucleic acid variants may be any length and that “a DNA segment encoding CHT refers to a DNA segment that contains wild-type, polymorphic or mutant CHT coding sequences yet is isolated away from, or purified free from, total mammalian genomic DNA. Included within the term “DNA segment,” are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like” (pg 23, lines 7-12; pg 30; pg 42). However, the claims do not require that the nucleic acid or polypeptide possess any particular

Art Unit: 1647

biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of nucleic acid molecules.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, there is not even identification of any particular portion of the nucleic acid structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus. Additionally, the description of one mCHT polynucleotide species (SEQ ID NO: 3) and one mCHT polypeptide species (SEQ ID NO: 4) is not adequate written description of an entire genus of functionally equivalent polynucleotides and polypeptides which incorporate all variants, fragments, and derivatives of SEQ ID NO: 3 and SEQ ID NO: 4.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (See *Vas-Cath* at page 1116).

With the exception of the sequences referred to above, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides, and therefore conception is

Art Unit: 1647

not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The nucleic acid itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only an isolated nucleic acid molecule consisting of the nucleic acid sequence of SEQ ID NO:3 and a nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:4, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 29-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1647

7. Claims 29-34 are rejected as being indefinite because the claims fail to define the metes and bounds of the phrase “comprising/having... essentially as set forth in SEQ ID NO:”. For example, it is not clear if this language is open or closed or what polynucleotides/polypeptides are encompassed.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 29-34 and 36 are rejected under 35 U.S.C. 102(b) as being anticipated by Okuda et al. (Nat Neurosci 3(2): 120-125, 2000; Genbank Accession No. AB030947). It is noted that the phrase “comprising/having ... essentially as set forth in SEQ ID NO:”, as recited in the claims, is broadly interpreted by the Examiner as reading upon: (i) nucleic acid variants of SEQ ID NO: 3 with any number of deletions, substitutions, or additions and (ii) protein variants of SEQ ID NO: 4 with any number of deletions, substitutions, or additions.

Okuda et al. teach an isolated “CHT1” polynucleotide that is 92.7% identical to the nucleic acid sequence of SEQ ID NO: 3 of the instant application (see sequence alignment attached to the instant Office Action as Appendix A). The CHT1 polynucleotide of Okuda et al. comprises a nucleic acid sequence that is identical to at least 134 contiguous nucleotides of SEQ ID NO: 3 of the instant application (see nucleic acids 1418-1551 of Okuda et al. and nucleic

Art Unit: 1647

acids 1195-1328 of SEQ ID NO:3 of the instant application). Okuda et al. also disclose that the CHT1 polynucleotide encodes a choline transporter polypeptide (see sequence alignment attached to the instant Office Action as Appendix B; see Figure 2a of Okuda et al.) Okuda et al. teach that the CHT1 cDNA is isolated and subcloned into the pcDNA3.1+ vector, which contains a cytomegalovirus immediate early (CMV) promoter/enhancer (pg 124, 2nd full paragraph). Okuda et al. disclose transfecting COS7 cells with the CHT1/pcDNA3.1+ vector (pg 124, Figure 5).

9. Claims 29-36 are rejected under 35 U.S.C. 102(a) as being anticipated by Haga et al. (WO 0116315; 08 March 2001; see also pg 24-25 of CA 2382464 (Canadian translation of WO 0116315)).

Haga et al. teach an isolated murine polynucleotide that is 99.3% identical to the nucleic acid sequence of SEQ ID NO: 3 of the instant application (see sequence alignment attached to the instant Office Action as Appendix C; see also SEQ ID NO: 7 of Haga et al.). The CHT1 polynucleotide of Haga et al. comprises a nucleic acid sequence that is identical to over 100 contiguous nucleotides of SEQ ID NO: 3 of the instant application (see nucleic acids 356-1733 of Haga et al. and nucleic acids 356-1733 of SEQ ID NO:3 of the instant application). Haga et al. also disclose that the CHT1 polynucleotide encodes a choline transporter polypeptide (see sequence alignment attached to the instant Office Action as Appendix D; see SEQ ID NO: 8 of Haga et al.) Haga et al. teach that the gene encoding the mCHT protein may be introduced into a host cell by a number of different methods (pg 22, lines 13-26). Haga et al. teach that vectors

Art Unit: 1647

may used as an expression system to express the protein in a host cell and that the vectors may contain a regulatory sequence that acts as a promoter (pg 23, lines 7-17).

Art Unit: 1647

Conclusion

No claims are allowable.

The art made of record and not relied upon is considered pertinent to applicant's disclosure:

Wu et al. (U.S. Patent 6,500,643) (SEQ ID NO : 1 of Wu et al. is 79.1% identical to SEQ ID NO: 3 of the instant application)


Invitrogen 2001 catalog, pg 155 (pcDNA vectors)

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bridget E. Bunner whose telephone number is (571) 272-0881. The examiner can normally be reached on 8:30-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BEB
Art Unit 1647
04 August 2006


**BRIDGET BUNNER
PATENT EXAMINER**

Appendix A

1441 ACTCTCTCCATGGTACCTCATCTTTTACCAACATTTGTGTTTCTATCTTCCCAAGTAT 1500
 1501 CTATTTGAAGTGGACCTTCCCTCCCAAAATAGATGATTTGATGCTGTTGTCGCAAGG 1560
 1501 CTATTTGAAGTGGACCTTCCCTCCCAAAATAGATGATTTGATGCTGTTGTCGCAAGG 1560
 1561 CACAGTGAAGAGACATGAGCAAGACCATCTTCTAGTCAAGAAATGAAATATCAAAATTAAT 1620
 1561 CACAGTGAAGAGACATGAGCAAGACCATCTTCTAGTCAAGAAATGAAATATCAAAATTAAT 1620
 1621 GAACCTGCACCTGTGAACCTTCCGAGACCTTCAACCTTCACTTCACTTCAACCAATTAAG 1680
 1621 GAACCTGCACCTGTGAACCTTCCGAGACCTTCAACCTTCACTTCACTTCAACCAATTAAG 1680
 1681 GAGGCTCTCTTGTGTTGTTTCCAGTCCGAGGGGCTGCGGACTGAAGATAAATTTACAA 1740
 1681 GAGGCTCTCTTGTGTTGTTTCCAGTCCGAGGGGCTGCGGACTGAAGATAAATTTACAA 1740
 1741 TGA 1743
 1741 TGA 1743

RESULT 9
 AB030947
 LOCUS
 DEFINITION Rattus norvegicus mRNA for high-affinity choline transporter CHT1, complete cds.
 ACCESSION AB030947
 VERSION AB030947.1 GI:6863033
 KEYWORDS choline transporter; high-affinity choline transporter CHT1.
 SOURCE Rattus norvegicus (Norway rat)
 ORGANISM Rattus norvegicus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 1 (sites)
 Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T. and Katsura, I.
 Identification and characterization of the high-affinity choline transporter
 Nat. Neurosci. 3 (2), 120-125 (2000)
 10649566
 2 (bases 1 to 4904)
 Okuda, T.
 Direct Submission
 Submitted (09-AUG-1999) Takashi Okuda, University of Tokyo, Faculty of Medicine, Department of Neurochemistry, Hongo 7-3-1, Bunkyo-ku 113-0033, Japan (E-mail: okuda@n.u-tokyo.ac.jp, Tel: +81-3-5841-3560, Fax: +81-3-3814-8154)
 Sequence updated (11-Jan-2000).
 Location/Qualifiers
 1..4904
 /organism="Rattus norvegicus"
 /mol_type="mRNA"
 /strain="Wistar"
 /db_xref="taxon:10116"
 /clone="CHT1"
 /tissue_type="spinal.cord"
 /clone_lib="rat spinal cord cDNA library"
 /dev_stage="adult"
 224..1966
 /codon_start=1
 /product="high-affinity choline transporter CHT1"
 /protein_id="BAA90484.1"
 /db_xref="GI:6863034"
 /transl_table="1"
 GGRDGLLVGGTWTATVGGGVTAEAVYVPGGLAWAQAIPGYSLSLILGLFF
 AKPMSKGYVTLDPFOQIYKRMGGLFIPALMGEMFWAAIPESALGARTSLIIVD
 VNISVYSALIALIYLVGLSVYAVDVLQFCIFGLWISVFPALSHPAVDIGFT
 AVHAKYQSMGLTIESVEVYTWLNDLMLMGVFPQWYFORVLSSSATYQVLSL
 AAFGLVWALPAICIGAGTSTWNTAYGPDPTKEADMLPIVLQICPVYISF
 FGLGAVSAAMSSADSSILSSAMFARNIYQLSPRONASDKIEIWNRIITVFEVGA

TAMALLTKTVGLWYLLSSDLVYIIIFPOLLCVLFKGTNTYGA VAGYIFGLFLRTTG
 EPLYLQPLIFYPGYDPKNGIYNORPFTKLSMVTSPFTNI CYSYLAKYFESGTLF
 PKLDIFDAVYRHSSENMKXILVRNENIKLNELAPVKRQSLTSLSTFTNKEALLDV
 DSSPESGSGTEDNLQ"

Query Match 92.7%; Score 1616.6; DB 6; Length 4904;
 Best Local Similarity 95.5%; Pred. No. 0;
 Matches 1664; Conservative 0; Mismatches 79; Indels 0; Gaps 0;

ORIGIN
 1 ATGCTTTTCCATGTGGAGGAGCTAGTATTTATCTCTTCTACCTCTTATTTCTG 60
 224 ATGCTTTTCCATGTAGAGGAGCTAGTATTTATCTCTTCTACCTCTTATTTCTG 283
 61 GTTGGAAATATGGCTGTCATGGAACCAAAACAGCGGCAACCCAGAGAGCGAGTAA 120
 284 GTTGGAAATATGGCTGTCATGGAACCAAAACAGCGGTAATGAGAGAGCGAGTAA 343
 121 GCCATCATATGTCGGGGCCGTCAGTATTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 180
 344 GCCATCATATGTCGGGGCCGTCAGTATTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 403
 181 ACCTGGGTTGGAGGAGCTACATCAATGGGAGAGAGAGAGAGAGAGAGAGAGAGAGT 240
 404 ACCTGGGTTGGAGGAGGTTATCAACCGGAGAGAGAGAGAGAGAGAGAGAGAGT 463
 241 GGTCTAGCTTGGGCTCATGCAACCACTTGGATATTTCTCTGAGTCTAAATTTAGTGGTCTG 300
 464 GGTCTAGCTTGGGCTCAGGCAACCACTTGGATATTTCTCTGAGTCTAAATTTAGTGGTCTG 523
 301 TTTTTCGGAACCTATGCGTTTCAAGGAGATATGATATTTAGTATGACCCATTTCAACAG 360
 524 TTTTTCGGAACCTATGCGTTTCAAGGAGATATGATATTTAGTATGACCCATTTCAACAG 583
 361 ATCTATGGAAGGCGATGGGTGGCTCTCTCTATCTCTGAGTATGAGGAGAGAGATGTT 420
 584 ATCTATGGAAGGCGATGGGTGGCTCTCTCTATCTCTGAGTATGAGGAGAGAGATGTT 643
 421 TGGGCTCAGCAATTTTCTCTGATTAAGGGCCACCATCAGCGTGATCATTTAGTATGATG 480
 644 TGGGCTCAGCAATTTTCTCTGATTAAGGGGCTACCATCAGCGTGATCATTTAGTATGATG 703
 481 GTGAACATATCGGTCAATTTCTCTGCACTCATTTGCCATTTCTTATACCCCTAGTGGGTGG 540
 704 GTGAACATATCGGTCAATTTCTCTGCACTCATTTGCCATTTCTTATACCCCTAGTGGGTGG 763
 541 CTCTACTCTCTGGCATATATGATGTTGTCAGTATTTCTGCACTTTTATAGGAGTGG 600
 764 CTCTACTCTCTGGCATATATGATGTTGTCAGTATTTCTGCACTTTTATAGGAGTGG 823
 601 ATCAGTGTCTCTTTTGGCTGTGCATCTCTGCACTCACCAGATCGGATTCACAGCTGTG 660
 824 ATCAGTGTCTCTTTTGGCTGTGCATCTCTGCACTCACCAGATCGGATTCACAGCTGTG 883
 661 CATGCTAAATACAGAGTCTCTGCTGGGAAACCAATGAATCAGTTGAAGTCTACACCTGG 720
 884 CATGCTAAATACAGAGTCTCTGCTGGGAAACCAATGAATCAGTTGAAGTCTACACCTGG 943
 721 CTTGATTAATTTCTGTTTATGATGCTGGGTGGAATCCCATGGGAGAGCTTCTCAGAGG 780
 944 CTTGATTAATTTCTGTTTATGATGCTGGGTGGAATCCCATGGGAGAGCTTCTCAGAGG 1003
 781 GTCTCTCTCTTCTCTCAGGACCTATGCTCAGTATGCTCTCTCTCTCTCTCTCTCTCTCT 840
 1004 GTCTCTCTCTCTCTCAGGACCTATGCTCAGTATGCTCTCTCTCTCTCTCTCTCTCTCTCT 1063
 841 TGCTGTGTGATGCTCTTACCGGCTATGATGATGAGGCTATTTGAGGCTTCCACAGAGTGG 900
 1064 TGCTGTGTGATGCTCTTACCGGCTATGATGATGAGGCTATTTGAGGCTTCCACAGAGTGG 1123
 901 AACAGAGTCTCTCTCAGGCTATGATGATGAGGCTATTTGAGGCTTCCACAGAGTGG 960
 1124 AACCAAACTCATATGGGTTTCCAGATCCCAAGAGAGAGAGAGAGAGAGAGAGATGATCTC 1183

QY	961	CCGATCGTTCTCGCAGTACCTCTGCGCCTGTGTACATCTCCTCTCTTGGGCTTGGTCTGTT	1020
4 Db	1184	CCGATTGTTCTACAGTACCTCTGCGCCTGTGTACATTTCTTCTTGGGCTTGGTCTGTT	1243
QY	1021	TCAGTCTGCTGTCATGTCTTCAGTCTGCTGCTCCATCTCTGTGCGGAGTTCCTATGTTTGCT	1080
Db	1244	TCGTCTGCTGTCATGTCTTCGCTCGCTGACTCATCTCTATCAGCAAGTTCCTATGTTGCT	1303
QY	1081	CGGAATATCTACACAGCTTTCCTTCAGACAAATGCATCAGACAGGAAATGTGTGGGTC	1140
Db	1304	CGGAATATCTACACGCTTTCCTTCAGACAAATGCATCAGACAGGAAATGTGTGGGTC	1363
QY	1141	ATGAGGATCATGTGCTTGTGTGGAGCATCTGCAACAGGCATCTGCTGACGCAAG	1200
Db	1364	ATGAGGATCATGTGTGTGTGTGGAGCATCTGCAACAGGCATCTGCTGACGCAAG	1423
QY	1201	ACTGTGTAATGGGCTCTGTACTGAGCTCTGACCTTGTCTACATCATCTTCCACAG	1260
Db	1424	ACTGTGTAATGGGCTCTGTGTACTGAGCTCTGACCTTGTCTACATCATCTTCCACAG	1483
QY	1261	CTGCTCTGTGTACTTTCATCAAAAGGAACCAACACTTATGGGCGAGTGTGGGTATATT	1320
Db	1484	CTGCTCTGTGTACTTTCATCAAAAGGAACCAACACTTATGGGCGAGTGTGGGTATATT	1543
QY	1321	TTTGGACTATTCGAGAAATTATGAGGAGAGCCATATCTATCTTCAGCCCTTAATC	1380
Db	1544	TTTGGACTTTTCTTGAGAAATTACCGGAGGAGAGCCATATCTATCTTCAGCCCTTAATC	1603
QY	1381	TTCTACCCCTGGTTATTACTCTGACAGAAATGGTATATCAATCAGAGGTTCCCAATTAAA	1440
Db	1604	TTCTACCCCTGGTTATTACCCTGACAGAAATGGTATATCAATCAGAGGTTCCCAATTAAA	1663
QY	1441	ACTCTCTCCAATGGTTACTCTTATTTACCAACATTTGTGTTTCTTATCTACGCCAGTAT	1500
Db	1664	ACTCTCTCCAATGGTTACTCTTATTTACCAACATTTGTGTTTCTTATCTACGCCAGTAT	1723
QY	1501	CTATTTGAAAGTGGAACTTGGCTCCAAAATTAGATGTATTTGATGCTGTGTCTCAAGG	1560
Db	1724	CTATTTGAAAGTGGAACTTGGCTCCAAAATTAGATGTATTTGATGCTGTGTCTCAAGG	1783
QY	1561	CACAGTGAAGAGAAATGGACAGACCATCTGATGTCAGAAATGAAATATCAAAATTAAT	1620
Db	1784	CACAGTGAAGAGAAATGACACAGACCATCTGATGTCAGAAATGAAATATCAAAATTAAT	1843
QY	1621	GAACTTGCACCTGTGAAAACCTCGGCAGAGCCATAACCTCAGTTCAACTTTTACCAATAAG	1680
Db	1844	GAACTTGCACCTGTGAAAACCTCGGCAGAGCCATAACCTCAGTTCAACTTTTACCAATAAG	1903
QY	1681	GAGGCCCTCTTCATGTTGATTTCCAGTCCGGAGGGGTCTGGAGATGAGATAATTTACAA	1740
Db	1904	GAGGCTCTCTTGATGTTGATTTCCAGTCCAGAGGGATCTGGGACTGGAAGATACTTACAA	1963
QY	1741	TGA	1743
Db	1964	TGA	1966

[illegible]

FEATURES
source

Location/Qualifiers
1. .4904
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/clone="CHT1"
/tissue_type="spinal cord"
/clone_lib="rat spinal cord cDNA library"
/dev_stage="adult"
224. .1966
/codon_start=1
/product="high-affinity choline transporter CHT1"
/protein_id="BAA90484.1"
/db_xref="GI:6863034"
/translation="MPFHVEGLVAIIIFYLLIFLVGIWAAWTKNGNAERSEAILIV
GGRDITGLVGGTWTATVTVGGGYINGTAETAVYGGCGLAWAQAIPGYSLSLILGLFF
AKPMKSGVYTWLDPDPOIYIGKRMGLLFI PALMGEMFWAAAI FSA LGATISVIDV
VNI SVLSALIAI LLYTLVGLSYAVTVVQLFCI FIGLWISVPFALSHPAVTDIGFT
AVHAKYQSPWLGTTIESVEVYTWLDNELLMLGGI PQHAYFORVLSSSASYAOVLSF
AFGCLVAMALPAICAGI GASTDNQTA YGFPDPKKEADMLPI VQLXILCPYVISF
FGLGVSAAVSAADSSILSASMFARNYQLSFRQNASDKEIWNVRITVFPVGA
TAMALLTKTVYGLWYLSDLVLI IFPQLLCVLIKGNTNYGAVGYIFGLFLRTG
EPVLYQPLIFYPGYVDKNGIYNORFPFKTSLSMVTSFFNTI CVSYLAKLYFESGILP
PKLIDFADVSRHSENMDKTILVRNENIKNELAPVKPQSLTSLSTFTNKEALLD
DSSPEGSGETDNLQ"

ORIGIN

Alignment Scores:
Pred. No.: 0 Length: 4904
Score: 2956.00 Matches: 572
Percent Similarity: 99.3% Conservative: 4
Best Local Similarity: 98.6% Mismatches: 4
Query Match: 98.8% Indels: 0
DB: 6 Gaps: 0

US-10-724-806-4 (1-580) x AB030947 (1-4904)

Qy	1	MetProPheHisValGluGlyLeuValAlaAlaIleLeuPheTyrLeuLeullePheLeu	20
Db	224	ATGCCCTTCATGTAGAGGACCTAGTAGCGATTATCTCTACCTTCATATATTTCTG	283
Qy	21	ValGlyIleTrpAlaAlaTrpLysThrLysAsnSerClyAsnProGluGluAAsgSerGlu	40
Db	284	GTTGGAATATGGGCTGCATGGAACCAAAAACGGCGGTAAATCAGAAGAACCGCAGCGAA	343
Qy	41	AlaIleIleValGlyGlyArgAspIleGlyLeuLeuValGlyGlyPheThrMetThrAla	60
Db	344	GCATCATAGTTGGGGCCGAGACATGTTGTTGTTGGTGGTGTTCACCATGACAGCC	403
Qy	61	ThrTrpValGlyGlyGlyTyrIleAsnGlyThrAlaGluAlaValTyrGlyProGlyCys	80
Db	404	ACCTGGGTTGGAGAGGTTACATCAACGGCACAGCTGAAGCAGTTTATGGCCAGGTGTG	463
Qy	81	GlyLeuAlaTrpAlaHisAlaProIleGlyTyrSerLeuSerLeulleIleLeuGlyGlyLeu	100
Db	464	GGTCTAGTTGGGCTCAGGCACCCATTGGATATCTCTGAGTCTGATTTTAGGTGGCCCTG	523
Qy	101	PhePheAlaLysProMetArgSerLysGlyTyrValThrMetLeuAspPropheLysGln	120
Db	524	TTTTTTTGCAAAACCTATCGCTTCAAGGGATATGTGACTATGTAGACCCGTTTCAACAG	583
Qy	121	IleTyrGlyLysArgMetGlyGlyLeuLeuPheIleProAlaLeuMetGlyGluMetPhe	140
Db	584	ATCTATGGAAGCGCATGGGTGGCTGCTCTTTCATCCCTGCACCTGATGGGAGAGATGTC	643
Qy	141	TrpAlaAlaAlaIlePheSerAlaLeuGlyAlaThrIleSerValIleIleAspValAsp	160
Db	644	TGGGCTGCAGCAATTTTCTCGCATTAGGGGCTACCATCAGCGGTAATCATTTGATGTGGAT	703
Qy	161	ValAsnIleSerValIleValSerAlaLeulleAlaIleLeuTyrThrLeuValGlyGly	180
Db	704	GTGAACATATCGGTCATTGTCTCCGACTCATTTGCCATTTCTTATACCTTCGTTGGGAGG	763

Qy 541 GluLeuAlaProValIysProArgGlnSerLeuThrLeuSerThrPheThrAsnLys 560
 Db 1844 GAACTTGGACCTGTAAAGCCCTCGACAGAGCTTAACCCCTCAGTTCAACTTCCACCAATAA 1903
 Qy 561 GluAlaLeuLeuAspValIasPserSerProGluGlySerGlyThrGluAspAsnLeuGln 580
 Db 1904 GAGGCTCTCCTTGCATGTTGATTCAGTCCAGTCCAGAGGGGATCTGGGACTGAAGATAACTTACAA 19633
 RESULT 10
 BD012719 1743 bp DNA linear PAT 02-AUG-2002
 LOCUS High-affinity choline transporter.
 DEFINITION
 ACCESSION BD012719
 VERSION BD012719.1 GI:22092908
 KEYWORDS WO 0116315-A/3.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
 Hominiidae; Homo.
 REFERENCE 1 (bases 1 to 1743)
 AUTHORS Haga,T. and Okuda,T.
 TITLE High-affinity choline transporter
 JOURNAL Patent: WO 0116315-A 3 08-MAR-2001;
 JOURNAL JAPAN SCIENCE AND TECHNOLOGY CORP, TATSUYA HAGA, TAKASHI OKUDA
 COMMENT OS Homo sapiens (human)
 PN WO 0116315-A/3
 PD 08-MAR-2001
 PF 18-AUG-2000 WO 2000/P005545
 PR 27-AUG-1999 JP 99P 240642, 27-DEC-1999 JP 99P 368991 PI
 TATSUYA HAGA, TAKASHI OKUDA
 PC C12N15/12,C07K14/47,C12Q1/68,C07K19/00,C07K16/18,C12N5/10, PC
 A61K38/17,
 PC A61K45/00,A61P25/28,G01N33/53,A01K67/027
 CC
 FH Key
 FT CDS Location/Qualifiers
 1..1743
 Location/Qualifiers
 1..1743
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 ORIGIN
 Alignment Scores:
 Pred. No.: 0 Length: 1743
 Score: 2795.00 Matches: 537
 Percent Similarity: 96.6% Conservative: 23
 Best Local Similarity: 92.6% Mismatches: 20
 Query Match: 93.4% Indels: 0
 DB: 2 Gaps: 0
 US-10-724-806-4 (1-580) x BD012719 (1-1743)
 Qy 1 MetProPheHisValGluGlyLeuValAlaLeuLeuPheThrLeuLeuPheLeu 20
 Db 1 ATGGCTTTTCATGTGGGAAGGACTGATAGCTATCATCGTTTCTCACTTCTAAATTTGCTG 60
 Qy 21 ValGlyIleTrpAlaAlaTrpLysThrLysAsnSerGlyAsnProGluGluArgSerGlu 40
 Db 61 GTTGGATATGGCTGCTCGAGAACCAAAAAACAGTGGCAGCGCAGAGAGCGCAGCGAA 120
 Qy 41 AlaIleLeuValGlyArgAspIleGlyLeuLeuValGlyGlyPheThrMetThrAla 60
 Db 121 GCATCATCATAGTTGGTGGCCGAGATATTGGTTATTTGGTTGGTATTACCATCAGCT 180
 Qy 61 ThrTrpValGlyGlyGlyTyrrIleAsnGlyThrAlaGluAlaValTyrrGlyProGlyCys 80
 Db 187 ACCTGGGTCCGAGGAGGGGTATATCAATGGCACAGCTGACGCGATTATGTACCACTTAT 240
 Qy 81 GlyLeuAlaTrpAlaHisAlaIleProIleGlyTyrSerLeuSerLeuLeuGlyLeu 100
 Db 241 GGCTTACTTGGCTCAGGCACCAATTTGGATTTCTCTTACTTCGATTATTTAGTTGGCTG 300

721 CTTGATATATTTCTGTTATTTGATGCTGGTGGATCCATCGCAAGCCTACTTCCAGAGG 780
DB CTTGATATATTTCTGTTATTTGATGCTGGTGGATCCATCGCAAGCCTACTTCCAGAGG 806
781 GTCCTCTCTTCATCTCCAGCACCTATGCTCAGTACTGTCTCTTCTGCGAGCTTTTGGG 840
DB GTCCTCTCTTCATCTCCAGCACCTATGCTCAGTACTGTCTCTTCTGCGAGCTTTTGGG 866
841 TGCTGGTGTGATGGCTCTACCGCCATATGCTATGAGCTATGAGCTTCCACAGACTGG 900
DB TGCTGGTGTGATGGCTCTACCGCCATATGCTATGAGCTATGAGCTTCCACAGACTGG 926
901 AACAGACTGCTACCGGTATCCAGATCCAGATCCAGATCTAAGAGGAGGAGCAGATGATCTC 960
DB AACAGACTGCTACCGGTATCCAGATCCAGATCTAAGAGGAGGAGCAGATGATCTC 986
927 AACAGACTGCTACCGGTATCCAGATCCAGATCTAAGAGGAGGAGCAGATGATCTC 986
961 CCGATCGTTCTGACGTAACCTCTGCGCTGTGATCATCTCTCTTTTGGGCTTGGTCTGTT 1020
DB CCGATCGTTCTGACGTAACCTCTGCGCTGTGATCATCTCTCTTTTGGGCTTGGTCTGTT 1046
1021 TCAGTGTGCTGATGCTCTCAGTACTGCTGCTCCATCTCTGCGGCGAGTTCTATGTTGCT 1080
DB TCAGTGTGCTGATGCTCTCAGTACTGCTGCTCCATCTCTGCGGCGAGTTCTATGTTGCT 1106
1047 TCAGTGTGCTGATGCTCTCAGTACTGCTGCTCCATCTCTGCGGCGAGTTCTATGTTGCT 1106
1081 CGGATATCTACAGCTTTCTCTTTCAGACAAATGATCAGACAAAGGAAATTTGTGGGTC 1140
DB CGGATATCTACAGCTTTCTCTTTCAGACAAATGATCAGACAAAGGAAATTTGTGGGTC 1166
1107 CGGATATCTACAGCTTTCTCTTTCAGACAAATGATCAGACAAAGGAAATTTGTGGGTC 1166
1141 ATGAGGATCACTGTGCTGTGTTGCGAGCATCTGCAACAGCCATGCTTGTGCTGAGAG 1200
DB ATGAGGATCACTGTGCTGTGTTGCGAGCATCTGCAACAGCCATGCTTGTGCTGAGAG 1226
1201 ACTGTGTATGGGCTGTGTTACCTGAGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
DB ACTGTGTATGGGCTGTGTTACCTGAGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1286
1261 CTGCTGTGTTACTCTTCAAGAAACCAACACTTATGCGGCGAGTTCTGCTGTTATAT 1320
DB CTGCTGTGTTACTCTTCAAGAAACCAACACTTATGCGGCGAGTTCTGCTGTTATAT 1346
1321 TTGAGACTATCTGAGATTTACTGAGAGAGCCATATCTATCTATCTGAGGCCCTTAATC 1380
DB TTGAGACTATCTGAGATTTACTGAGAGAGCCATATCTATCTATCTGAGGCCCTTAATC 1406
1381 TTCTACCTGGTTTACTCTGACAGATGTTATATCAATCAGAGGTTTCCCAATTTAA 1440
DB TTCTACCTGGTTTACTCTGACAGATGTTATATCAATCAGAGGTTTCCCAATTTAA 1466
1407 TTCTACCTGGTTTACTCTGACAGATGTTATATCAATCAGAGGTTTCCCAATTTAA 1466
1441 ACTCTCTCCATGTTACTCTTCTTACCACATTTGTTGTTTCTTATCTAGCCAAAGTAT 1500
DB ACTCTCTCCATGTTACTCTTCTTACCACATTTGTTGTTTCTTATCTAGCCAAAGTAT 1526
1501 CTATTTGAAAGTGGAACTTTCCTTCCAAATTTAGATGTTATGATGTTGTTGCGAAG 1560
DB CTATTTGAAAGTGGAACTTTCCTTCCAAATTTAGATGTTATGATGTTGTTGCGAAG 1586
1561 CACAGTGAAGAGACATGGAACCATTTCTAGTCAGAAATGAAATATCAAAATTAAT 1620
DB CACAGTGAAGAGACATGGAACCATTTCTAGTCAGAAATGAAATATCAAAATTAAT 1646
1587 CACAGTGAAGAGACATGGAACCATTTCTAGTCAGAAATGAAATATCAAAATTAAT 1646
1621 GAACTTCACCTGTGAAACCTTGGCAGAGCTAACCTCTAGTTCAACTTTTCCCAATTAAG 1680
DB GAACTTCACCTGTGAAACCTTGGCAGAGCTAACCTCTAGTTCAACTTTTCCCAATTAAG 1706
1681 GAGGCCCTCTCTGATGTTGATTTCCAGTCCGAGGGGCTTGGGCTGAAGATATTTACAA 1740
DB GAGGCCCTCTCTGATGTTGATTTCCAGTCCGAGGGGCTTGGGCTGAAGATATTTACAA 1766
1707 GAGGCCCTCTCTGATGTTGATTTCCAGTCCGAGGGGCTTGGGCTGAAGATATTTACAA 1766
1741 TGA 1743
1767 TGA 1769

RESULT 3
BD012720
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
ORIGIN
Query Match 99.3%; Score 1730.2; DB 2; Length 1743;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1735; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1 ATGCTTTTCCATGTGGAAGAGCTGCTAGCTATATTCCTTCTTCTACCTCTTATATTTCTG 60
DB 1 ATGCTTTTCCATGTGGAAGAGCTGCTAGCTATATTCCTTCTTCTACCTCTTATATTTCTG 60
QY 61 GTTGAATATGGCTGCTATGGAACCAAAAACAGCGGCAACCCAGAGAGCAGTGA 120
DB 61 GTTGAATATGGCTGCTATGGAACCAAAAACAGCGGCAACCCAGAGAGCAGTGA 120
QY 121 GCATCATAGTCGGGGCGCTGACATTCATTCATTCATTCATTCATTCATTCATTCATTCAT 180
DB 121 GCATCATAGTCGGGGCGCTGACATTCATTCATTCATTCATTCATTCATTCATTCATTCAT 180
QY 181 ACCTGGTTGGAGGAGGCTTACATCAATGGGAGCAGAGCAGTGTATGGGCGAGTTGT 240
DB 181 ACCTGGTTGGAGGAGGCTTACATCAATGGGAGCAGAGCAGTGTATGGGCGAGTTGT 240
QY 241 GGTCTAGCTTGGGCTCATGCAACCATTCATTCATTCATTCATTCATTCATTCATTCATTCAT 300
DB 241 GGTCTAGCTTGGGCTCATGCAACCATTCATTCATTCATTCATTCATTCATTCATTCATTCAT 300
QY 301 TTTTTCGCAACCTTATGCGTTTCCAGGAGTATGACTATGTTAGCCCATTTCAACAG 360
DB 301 TTTTTCGCAACCTTATGCGTTTCCAGGAGTATGACTATGTTAGCCCATTTCAACAG 360
QY 361 ATCTATGGAAGCAGCAGTGGTGGCTGCTCTTTCATCCCTGCACTGATGGGAGAGATTTTC 420
DB 361 ATCTATGGAAGCAGCAGTGGTGGCTGCTCTTTCATCCCTGCACTGATGGGAGAGATTTTC 420
QY 421 TGGGCTGCAAGCAATTTTCTCTGATTTAGGGGCCCATCAGCGTGTATTCATTTGATTTGGAT 480
DB 421 TGGGCTGCAAGCAATTTTCTCTGATTTAGGGGCCCATCAGCGTGTATTCATTTGATTTGGAT 480

BD012720
High-affinity choline transporter.
BD012720
BD012720.1 GI:22092909
WO 0116315-A/4.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
Sciurognathi; Muridae; Muridae; Muridae; Mus.
1 (bases 1 to 1743)
Haga, T. and Okuda, T.
High-affinity choline transporter
Patent: WO 0116315-A 4 08-MAR-2001;
JAPAN SCIENCE AND TECHNOLOGY CORP, TATSUYA HAGA, TAKASHI OKUDA
OS Mus musculus (mouse)
PN WO 0116315-A/4
PD 08-MAR-2001
PF 18-AUG-2000 WO 2000JP005545
PR 27-AUG-1999 JP 99P 240642, 27-DEC-1999 JP 99P 368991 PI
TATSUYA HAGA, TAKASHI OKUDA
PC C12N15/12, C07K14/47, C12Q1/68, C07K19/00, C07K16/18, C12N5/10, PC
A61K38/17,
PC A61K45/00, A61P25/28, G01N33/53, A01K67/027
CC
FH Key Location/Qualifiers
FT CDS Location/Qualifiers
1. 1743
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

Appendix C

481 GTCAACATATCGGTCTGCTGACCTCATTCGCACTCTTTATACCTAGTGGTGG 540
 481 GTGACATATCGGTCTGCTGACCTCATTCGCACTCTTTATACCTAGTGGTGG 540
 541 CTCTACTCTGTGTCATATGATGATGTCACGTAATTCGCAATTTTATPAGAGTGTG 600
 541 CTCTACTCTGTGTCATATGATGATGTCACGTAATTCGCAATTTTATPAGAGTGTG 600
 601 ATCAGTGTCCCTTTTGGCCCTGTCACATCTGTCAGTCAACGACATCGAATTCACAGCTGTG 660
 601 ATCAGTGTCCCTTTTGGCCCTGTCACATCTGTCAGTCAACGACATCGAATTCACAGCTGTG 660
 661 CATGCTAATATACAGAGTCCCTGGCTGGGAAACCAATGAAATCAGTCAAGCTTACACCTGG 720
 661 CATGCTAATATACAGAGTCCCTGGCTGGGAAACCAATGAAATCAGTCAAGCTTACACCTGG 720
 721 CTTGATAATTTCTGTTATGATGCTGGTGGGAAATCCATGGCAAGCTTACACAGAG 780
 721 CTTGATAATTTCTGTTATGATGCTGGTGGGAAATCCATGGCAAGCTTACACAGAG 780
 781 GTCCCTCTCTCATCTCAGCCACTATGCTCAGTACTGCTCTTCTGCGAGCTTTTGGG 840
 781 GTCCCTCTCTCATCTCAGCCACTATGCTCAGTACTGCTCTTCTGCGAGCTTTTGGG 840
 841 TGCCCTGTGATGGCTCTACCCGCCATATGATAGGAGCTATTCGAGCTTCCACAGACTGG 900
 841 TGCCCTGTGATGGCTCTACCCGCCATATGATAGGAGCTATTCGAGCTTCCACAGACTGG 900
 901 AACCAGACTGCTACGGGTATCAGATCCAGACTAAGAGGAAGCAGATGATCTTC 960
 901 AACCAGACTGCTACGGGTATCAGATCCAGACTAAGAGGAAGCAGATGATCTTC 960
 961 CGATCGTCTGCAAGTCTCTCCCTGCTGTACATCTCTCTTCTGCGCTTGTGCTGT 1020
 961 CGATCGTCTGCAAGTCTCTCCCTGCTGTACATCTCTCTTCTGCGCTTGTGCTGT 1020
 1021 TCAGTCTGTCTCATGTCCTCAGCTGATCTGCTCCATCTGTCGCGAGTCTTATGTTTGTCT 1080
 1021 TCAGTCTGTCTCATGTCCTCAGCTGATCTGCTCCATCTGTCGCGAGTCTTATGTTTGTCT 1080
 1081 CGGAATATCTACAGCTTCTTTCAGCAAAATGCAATCAGCAAGGAATTTGTGGTCTC 1140
 1081 CGGAATATCTACAGCTTCTTTCAGCAAAATGCAATCAGCAAGGAATTTGTGGTCTC 1140
 1141 ATCAGATCACTGCTGTGTTGTCGAGCATCTGCAACGACCATGCTTGTGTCGAGAG 1200
 1141 ATCAGATCACTGCTGTGTTGTCGAGCATCTGCAACGACCATGCTTGTGTCGAGAG 1200
 1201 ACTGTATGGGCTCTGGTACCTGAGCTCTGACCTTGTCTACATCATCTTCCACAG 1260
 1201 ACTGTATGGGCTCTGGTACCTGAGCTCTGACCTTGTCTACATCATCTTCCACAG 1260
 1261 CTGCTCTGTGTAATCTTTCATCAAGGAACCAACACTTATGGGCAATGCTGTTATAT 1320
 1261 CTGCTCTGTGTAATCTTTCATCAAGGAACCAACACTTATGGGCAATGCTGTTATAT 1320
 1321 TTGGAATATCTGAGAAATCTGAGGAGGAGCCATATCTACTTTCAGGCTTAAATC 1380
 1321 TTGGAATATCTGAGAAATCTGAGGAGGAGCCATATCTACTTTCAGGCTTAAATC 1380
 1381 TTCTACCTCGTTTATTAATCTGACAGAAATGATATATACATCAGAGTTTCCATTTAAA 1440
 1381 TTCTACCTCGTTTATTAATCTGACAGAAATGATATATACATCAGAGTTTCCATTTAAA 1440
 1441 ACTCTCTCAATGTTACCTCATTTTACCAACATTTGTTTCTTATCTAGGCAAGTAT 1500
 1441 ACTCTCTCAATGTTACCTCATTTTACCAACATTTGTTTCTTATCTAGGCAAGTAT 1500
 1501 CTATTTGAAAGTGAACCTTGGCTCCAAATTTAGATGTTTCTGCTGTGTCGCAAG 1560
 1501 CTATTTGAAAGTGAACCTTGGCTCCAAATTTAGATGTTTCTGCTGTGTCGCAAG 1560
 1561 CACAGTGAAGAGAAATGGAACAGCAATTTCTAGTCAGAAATGAAATATCAAAATTTAAAT 1620

1561 CACAGTGAAGAGAAATGGAACAGCAATTTCTAGTCAGAAATGAAATATCAATTTAAAT 1620
 1621 GAACTTGACCTGTGAAACCTCGGAGAGCCCTAAACCTCAGTTCACCTTACCAATAG 1680
 1621 GAACTTGACCTGTGAAACCTCGGAGAGCCCTAAACCTCAGTTCACCTTACCAATAG 1680
 1681 GAGGCCCTCTTGTGATTTGATTCAGTCCGAGGGGTCTGGGACTGAAGATATTTACAA 1740
 1681 GAGGCCCTCTTGTGATTTGATTCAGTCCGAGGGGTCTGGGACTGAAGATATTTACAA 1740
 1741 TGA 1743
 1741 TGA 1743

RESULT 4
 E49872
 LOCUS High-affinity choline transporter. 1743 bp DNA linear PAT 27-AUG-2002
 DEFINITION
 ACCESSION E49872
 VERSION E49872.1 GI:22554903
 KEYWORDS JP 2001136976-A/4.
 SOURCE Mus sp.
 ORGANISM Mus sp.
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
 Sciurognathi; Muridae; Murinae; Mus
 1 (bases 1 to 1743)
 AUTHORS Haga, T. and Okuda, T.
 TITLE High-affinity choline transporter
 JOURNAL Patent: JP 2001136976-A 4 22-MAY-2001;
 SCIENCE & TECH AGENCY
 COMMENT OS Mus sp. (mouse)
 PN JP 2001136976-A/4
 PD 22-MAY-2001
 PF 27-DEC-1999 JP 1999368991
 PI TATSUYA HAGA, TAKASHI OKUDA
 PC C12N15/09, A01K67/027, A61K68/00, C07K14/47, C07K16/18, C07K19/00,
 PC C12N5/10,
 PC C12P21/02, C12P21/08, C12P21/00, C12N15/00, A61K37/02, C12N5/00 CC
 PH Key Location/Qualifiers
 FT CDS (1) (1743).

FEATURES
 source
 1. 1743
 /organism="Mus sp."
 /mol_type="genomic DNA"
 /db_xref="taxon:10095"

ORIGIN
 Query Match 98.3%; Score 1730.2; DB 2; Length 1743;
 Best Local Similarity 99.5%; Pred. No. 0;
 Matches 1735; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 ATGCTCTTCTGATGTCGAGAGGACTGCTAGCTATTTATCTCTTACCTCCTTATATTTCTG 60
 DB 1 ATGCTCTTCTGATGTCGAGAGGACTGCTAGCTATTTATCTCTTCTTACCTCCTTATATTTCTG 60
 QY 61 GTTGAATATGTCGTCATGGAACCAAAACAGCGGCAACCCAGAGAGCGAGTGAA 120
 DB 61 GTTGAATATGTCGTCATGGAACCAAAACAGCGGCAACCCAGAGAGCGAGTGAA 120
 QY 121 GCATCATAGTCGGGGCGCTGACATTTGTTTGTGTTTGTGTTTACCATGACAGCC 180
 DB 121 GCATCATAGTCGGGGCGCTGACATTTGTTTGTGTTTGTGTTTACCATGACAGCC 180
 QY 181 ACCTGGTGTGAGGAGGCTTACATCAATGGGACAGAGAGAGTGTATGGGCCAGGTTGT 240
 DB 181 ACCTGGTGTGAGGAGGCTTACATCAATGGGACAGAGAGAGTGTATGGGCCAGGTTGT 240
 QY 241 GGTCTAGCTTGGGCTCATGCAACCCATTTGATATTTCTGAGTCTAATTTTAGTGGTCTG 300
 DB 241 GGTCTAGCTTGGGCTCATGCAACCCATTTGATATTTCTGAGTCTAATTTTAGTGGTCTG 300

Appendix D

387 ATCTATGAAAGCGCATGGTGGCTGCTCTTTCATCCCTGCATGATGGAGAGATGTTTC 449
 141 TTPAlaAlaAlaIlePheSerAlaLeuGlyAlaThrIleSerValIleIleAspValAsp 760
 447 TGGGCTGCGACGAATTTCTCTGATTTAGGGGCCACCATCAGCTGATCATTTGATGTGGAT 506
 161 ValAsnIleSerValIleValSerAlaLeuIleAlaIleLeuTyrThrLeuValGlyGly 180
 507 GTGAACATATCGTCTATTGCTCTGCACATCTGTCATTTCTTATACCTTAGTGGTGGG 566
 181 LeuTyrSerValAlaTyrThrAspValValGlnLeuPheCysIlePheIleGlyLeuTyr 200
 567 CTCCTACTCTGTGGCATATATGATGTGTCCAGCTATTCTGCATTTTATATAGACTGTGG 626
 201 IleSerValProPheAlaLeuSerHisProAlaValThrAspIleGlyPheThrAlaVal 220
 627 ATCAGTGTCCCTTTTCCCTGTGCATCTGCTGAGTCCAGCATCCGACATCCATTCACAGCTGTG 686
 221 HisAlaLysTyrGlnSerProTyrLeuGlyThrIleGluSerValGluValTyrThrTyr 240
 687 CATGCTAATACACAGATCCCTGGCTGGGAACCATTTGAATCATTTGAACTTACACCTGG 746
 241 LeuAspAsnPheLeuLeuLeuMetLeuGlyGlyIleProTyrGlnAlaTyrPheGlnArg 260
 747 CTTGATAATTTCTGTATTATGATGCTGGGTGGAATCCCAAGGCAAGCTTACTTCCAGAGG 806
 261 ValLeuSerSerSerSerAlaThrTyrAlaGlnValLeuSerPheLeuAlaIlePheGly 280
 807 GTCCCTCTCTTCATCTCAGCCACCTATGCTGAGTATCTGCTCTCTGCGACCTTTTGGG 866
 281 CysLeuValMetAlaLeuProAlaIleCysIleGlyAlaIleGlyAlaSerThrAspTyr 300
 867 TGCCTGGTATGCTCTACCGCCATATGCAAGAGCTATTGAGCTTCCACAGACTGG 926
 301 AsnGlnThrAlaTyrGlyTyrProAspPheLysThrLysGluAlaAspMetIleLeu 320
 927 AACCAAGACTGCTCAGGGTATCCAGATCCCAAGACTAAGAGAGAGACACATGATTTCTC 986
 321 ProIleValLeuGlnTyrLeuCysProValTyrIleSerPhePheGlyLeuGlyAlaVal 340
 987 CCGATCGTCTCGATGACTCTGCTGATGATCATCTCTCTTTGGGCTTGGTGTCTGT 1046
 341 SerAlaAlaValMetSerSerPheAspSerSerIleLeuSerAlaSerSerMetPheAla 360
 1047 TCAGCTGCTGTCTATGCTCTCAGCTGCTGCTCCATCTCTGCGCGAGTCTATGTTGCT 1106
 361 ArgAsnIleTyrGlnLeuSerPheArgGlnAsnAlaSerAspLysGluIleValTyrVal 380
 1107 CGGAATATCTACAGCTTCTCTTCAGACAAAATGCAATGCAACAGAAATTTGTGTGGTCTC 1166
 381 MetArgIleThrValLeuValPheGlyAlaSerAlaThrAlaMetAlaLeuLeuThrLys 400
 1167 ATGAGATCATCTGCTGTGTGTCGAGCATCTGCAACAGCCATGCTTGTGTCAGCAAG 1226
 401 ThrValTyrGlyLeuTyrTyrLeuSerSerAspLeuValTyrIleIleIlePheProGln 420
 1227 ACTGTGATATGGCTCTGGTACCTGAGCTGACCTGTGCTACATCATCATCTTCCACAG 1286
 421 LeuLeuCysValLeuPheIleLysGlyThrAsnThrTyrGlyAlaValAlaGlyTyrIle 440
 1287 CTGCTGAGTGTACTCTTCAAGAAACCAACACTATGCGGCGAGTGTGCTGTTATATT 1346
 441 PheGlyLeuPheLeuArgIleThrGlyGlyGluProTyrLeuTyrLeuGlnProIle 460
 1347 TTTGAGCTATTCTGAGAAATTAATCTGAGAGAGCCATATCATATCTTGCAGCCCTTAATC 1406
 461 PheTyrProGlyTyrTyrSerAspLysAsnGlyIleTyrAsnGlnArgPheProPheLys 480
 1407 TTTACCTCTGTTATTACTCTGACAAGAAATGATATATACATCATCAGAGTTCCTCATTA 1466
 481 ThrLeuSerMetValThrSerPhePheThrAsnIleCysValSerTyrLeuAlaLysTyr 500
 1469 ACTCTCTCCATGGTTACCTCATTTCTTACCAACATTTGTTGTTCTTATCTAGCCCAAGTAT 1526

501 LeuPheGluSerGlyThrLeuProLysLeuAspValPheAspAlaValValAlaArg 520
 1527 CTAATTGAAGTGGAACTTGCCTCCAAATTAGATGATATTGATCTGTTGTCGCAAGG 1586
 521 HisSerGluGluAsnMetAspLysThrIleLeuValAsnGluAsnIleLysLeuAsn 540
 1587 CACGTGAAGAGACATGACACAGCACTTCTGTCAGAAATGAATAATCAATTAAT 1646
 541 GluLeuAlaProValLysProArgGlnSerLeuThrLeuSerSerThrPheThrAsnLys 560
 1647 GAACCTGCACCTGTGAAACCTGCGCAGAGCCCTAACCTCAGTTCACCTTCCACCAATAG 1706
 561 GluAlaLeuLeuAspValAspSerSerProGluGlySerGlyThrGluAspAsnLeuGln 580
 1707 GAGGCCCTCTCTGATGTTGATTCAGTCCGAGGGGCTCTGGGACTGAAGATAACTTACAA 1766

RESULT 3
 BD012720 1743 bp DNA linear PAT 02-AUG-2002
 LOCUS High-affinity choline transporter.
 DEFINITION BD012720
 ACCESSION BD012720.1 GI:22092909
 VERSION WO 0116315-A/4.
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
 Sciurognathi; Muridea; Muridae; Murinae; Mus.
 1 (bases 1 to 1743)
 AUTHORS Haga, T. and Okuda, T.
 TITLE High-affinity choline transporter
 JOURNAL Patent: WO 0116315-A 4 08-MAR-2001;
 JAPAN SCIENCE AND TECHNOLOGY CORP, TATSUYA HAGA, TAKASHI OKUDA
 COMMENT OS Mus musculus (mouse)
 PN WO 0116315-A/4
 PD 08-MAR-2001
 PF 18-AUG-2000 WO 2000JP005545
 PR 27-AUG-1999 JP 99P 240642, 27-DEC-1999 JP 99P 368991 PI
 TATSUYA HAGA, TAKASHI OKUDA
 PC C12N15/12, C07K14/47, C12Q1/68, C07K19/00, C07K16/18, C12N5/10, PC
 A61K38/17,
 PC A61K45/00, A61P25/28, G01N33/53, A01K67/027
 CC
 FH
 FT CDS Location/Qualifiers
 1..1743
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10090"

Alignment Scores:
 Pred. No.: 0 Length: 1743
 Score: 2968.00 Matches: 576
 Percent Similarity: 99.5% Conservative: 1
 Best Local Similarity: 99.3% Mismatches: 3
 Query Match: 99.2% Indels: 0
 DB: 2 Gaps: 0

US-10-724-806-4 (1-580) x BD012720 (1-1743)
 Qy 1 MetProPheHisValGluGlyLeuValAlaIleIleLeuPheTyrLeuLeuIlePheLeu 20
 Db 1 ATGCTCTTCCACGTAGAAGGACTGCTAGCTATTATCTCTTCTACCTCTTATATTCTG 60
 Qy 21 ValGlyIleTyrPalaAlaTyrLysThrLysAsnSerGlyAsnProGluGluArgSerGlu 40
 Db 61 GTTGGAAATATGGCTGCTGATGAAACCAAAACAGGGGCAACCCAGAGAGACAGTGA 120
 Qy 41 AlaIleIleValGlyGlyArgAspIleGlyLeuValGlyGlyPheThrMetThrAla 60

Db 121 GCCATCATAGTCGGGGCGGTGACATTCGTTTGGTGGTGGTTTACCATGACAGCC 180
*Qy 61 ThrTrpValGlyGlyGlyThrIleAsnGlyThrAlaGluAlaValTyrglyProGlyCys 80
Db 181 ACCTGGGTGGAGAGGCTACATCAATGGGACAGCAAGAGTGTATGGCCAGGTTGT 240
Qy 81 GlyLeuAlaTrpAlaHisAlaProIleGlyTyrsSerLeuSerLeuIleLeuGlyGlyLeu 100
Db 241 GGTCTAGTCTGGGCTCAGGCACCCATTCGATATTCCTGAGTCTAATTTTAGTGGTCTG 300
Qy 101 PhePheAlaLysProMetArgSerLysGlyTyrsValThrMetLeuAspProPheLysGln 120
Db 301 TTTTTCGAAACCTATGCGTTCCAGGAGATATGTGACTATGTATAGACCCATTTCAACAG 360
Qy 121 IleTyrglyLysArgMetGlyGlyLeuPheIleProAlaLeuMetGlyGluMetPhe 140
Db 361 ATCTATGGAAGCGCATGGGTGGGTCTCTTCATCCCTGCACTGATGGAGAGATGTTTC 420
Qy 141 TrpAlaAlaAlaIlePheSerAlaLeuGlyAlaThrIleSerValIleIleAspValAsp 160
Db 421 TGGGCTGCAGCAATTTCTCTGCAATTAGGGGCCACCATCAGCGTGATCATTTGATGGAT 480
Qy 161 ValAsnIleSerValIleValSerAlaLeuIleAlaIleLeuTyrsThrIleValGlyGly 180
Db 481 GTGAACATATCGGTATGTCCTGCACTCATTTGCCATTTCTTTATACCTTAGTGGGTGG 540
Qy 181 LeuTyrsSerValAlaTyrsThrAspValValGlnLeuPheCysIlePheIleGlyLeuTrp 200
Db 541 CTCTACTCTGTGGCATATCTGATGTTGTCAGCTATTCCTGCAATTTTATAGAGCTGTGG 600
Qy 201 IleSerValProPheAlaLeuSerHisProAlaValThrAspIleGlyPheThrAlaVal 220
Db 601 ATCAGTGTCCCTTTTGGCTGTGCATCTGTCAGTCACCGACATCGGATTCACAGCTGTG 660
Qy 221 HisAlaLysTyrglnSerProTrpLeuGlyThrIleGluSerValGluValTyrsThrTrp 240
Db 661 CATGCTAAATACACAGAGTCCCTGGTGGGAACCATTTGAATCAGTTGAAAGCTTACACCTGG 720
Qy 241 LeuAspAsnPheLeuLeuLeuMetLeuGlyGlyIleProTrpGlnAlaTyrsPheGlnArg 260
Db 721 CTTGATAATTTTCTGTATTGATGCTGGGTGGATCCCATGGCAAGCTTACTTCCAGAGG 780
Qy 261 ValLeuSerSerSerAlaThrTyrsAlaGlnValLeuSerPheLeuAlaAlaPheGly 280
Db 781 GTTCCTCTTCTATCTCACCACCATGCTCAGGACTCTCTCTCTCTGTCAGCTTTTGGG 840
Qy 281 CysLeuValMetAlaLeuProAlaIleCysIleGlyAlaIleGlyAlaSerThrAspTrp 300
Db 841 TGCCTGGTGTATGCTCTACCCGCAATATGATAGGAGCTATTTGGAGCTTCCACAGACTGG 900
Qy 301 AsnGlnThrAlaTyrsGlyTyrsProAspProLysThrLysGluAlaAlaAspMetIleLeu 320
Db 901 AACCCAGACTGCCTACGGGTATCCAGATCCCAAGACTAAGAGGAGGACACATGATTCCTC 960
Qy 321 ProIleValLeuGlnTyrsLeuCysProValTyrsIleSerPhePheGlyLeuGlyAlaVal 340
Db 961 CGAGTCGTCGAGGACCTCTCTCCCTGTGTATCTCTCTCTCTGGCTGGTGGTGTGT 1020
Qy 341 SerAlaAlaValMetSerSerAlaAspSerSerIleLeuSerAlaSerMetPheAla 360
Db 1021 TCAGTGTGTATGCTCTCAGCTGACTCGTCCATCTCTGTCGGCGAGTTCTATGTTTGTCT 1080
Qy 361 ArgAsnIleTyrglnLeuSerPheArgGlnAsnAlaSerAspLysGluIleValTrpVal 380
Db 1081 CGGAATATCTACAGGCTTCTCTTCAGACAAATATGCATCAGACAGGAAATGTTGTGGGTC 1140
Qy 381 MetArgIleThrValLeuValPheGlyAlaSerAlaThrAlaMetAlaLeuLeuThrLys 400
Db 1141 ATGAGGATCATCTGTCTGTGTGTCGGAGCATCTGCACACCATGCTTGTCTGCGAGAG 1200
Qy 401 ThrValTyrglyLeuTrpTyrsLeuSerSerAspLeuValTyrsIleIleIlePheProGln 420
Db 1201 ACTGTATGGGCTCTGTACCTGAGCTCTGACCTGTCTGCTTGTCTTACATCATCTTCCACAG 1260

Qy 421 LeuLeuCysValLeuPheIleLysGlyThrAsnThrTyrsGlyAlaValAlaGlyTyrsIle 440
Db 1261 CTGCTCTGTGTACTCTTTCATCAAGGAACCAACACATATATGGGACGATCTGTGTATATT 1320
Qy 441 PheGlyLeuPheLeuArgIleThrGlyGlyGluProTyrsLeuGlnProLeuIle 460
Db 1321 TTTGAGACTATTCCTGAGATTTACTTGGAGGAGGACCATATCTATCTTTCGAGCCCTTAATC 1380
Qy 461 PheTyrsProGlyTyrsTyrsAspLysAsnGlyIleTyrsAsnGlnArgPheProPheLys 480
Db 1381 TTCTACCTGGTTATTACTCTGACAAGAATGGTATATACAAATCAGAGGTTCCCATTTAAA 1440
Qy 481 ThrLeuSerMetValThrSerPhePheThrAsnIleCysValSerTyrsLeuAlaLysTyrs 500
Db 1441 ACTCTCTCCATGGTTACTCTTCTTACCAACATTTGTGTCTTCTTATCTAGCCAAGTAT 1500
Qy 501 LeuPheGluSerGlyThrLeuProProLysLeuAspValPheAspAlaValAlaAlaArg 520
Db 1501 CTATTTGAAAGTGGAACTTGCCTCCAAAATTAGATGTATTTGATGCTGTGTGCGCAAGG 1560
Qy 521 HisSerGluGluAsnMetAspLysThrIleLeuValArgAsnGluAsnIleLysLeuAsn 540
Db 1561 CACAGTGAAGACATCGACAGACCATCTTAGTCAGAAATGAAAATATCAAAATTAAT 1620
Qy 541 GluLeuAlaProValLysProArgGlnSerLeuThrLeuSerSerThrPheThrAsnLys 560
Db 1621 GAACCTGCACCTGTGAAACCTCGGACAGAGCTTACCCCTCAGTTCAACTTTTCCCAATAAG 1680
Qy 561 GluAlaLeuLeuAspValAspSerSerProGluGlySerGlyThrGluAspAsnLeuGln 580
Db 1681 GAGGCCCTCTTGTATGTTGATTCAGTCCGAGGGGCTCTGGAGCTGAAGATAACTTACAA 1740

RESULT 4

E49872 LOCUS E49872 1743 bp DNA linear PAT 27-AUG-2002
DEFINITION High-affinity choline transporter.
ACCESSION E49872
VERSION E49872.1 GI:22554903
KEYWORDS JP 2001136976-A/4.
SOURCE Mus sp.
ORGANISM Mus sp.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
Sciurognathi; Muridea; Muridae; Murinae; Mus.

REFERENCE
1 (bases 1 to 1743)
Haga, T. and Okuda, T.
AUTHORS
High-affinity choline transporter
TITLE
Patent: JP 2001136976-A 4 22-MAY-2001;
JOURNAL SCIENCE & TECH AGENCY

COMMENT

OS Mus sp. (mouse)
PN JP 2001136976-A/4
PD 22-MAY-2001
PF 27-DEC-1999 JP 1999368991
PI TATSUYA HAGA, TAKASHI OKUDA
PC C12N15/09, A01K67/027, A61K38/00, C07K14/47, C07K16/18, C07K19/00,
PC C12N5/10,
PC C12P21/02, C12P21/08, C12Q1/00, C12N15/00, A61K37/02, C12N5/00 CC
PH Key Location/Qualifiers
FT CDS (1)..(1743).

FEATURES

source

1..1743
/organism="Mus sp."
/mol_type="genomic DNA"
/db_xref="taxon:10095"

ORIGIN

Alignment Scores:

Pred. No.: 0 Length: 1743
Score: 2968.00 Matches: 576
Percent Similarity: 99.5% Conservative: 1
Best Local Similarity: 99.3% Mismatches: 3
Query Match: 99.2% Indels: 0